Nationwide Fund Advisors grew its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 3.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 111,757 shares of the biopharmaceutical company’s stock after buying an additional 3,742 shares during the quarter. Nationwide Fund Advisors owned approximately 0.09% of Celldex Therapeutics worth $276,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in CLDX. BB&T Securities LLC acquired a new position in shares of Celldex Therapeutics in the second quarter worth about $117,000. Overbrook Management Corp acquired a new position in shares of Celldex Therapeutics in the second quarter worth about $139,000. Pacad Investment Ltd. acquired a new position in shares of Celldex Therapeutics in the second quarter worth about $150,000. Creative Planning boosted its holdings in shares of Celldex Therapeutics by 12.2% in the second quarter. Creative Planning now owns 80,136 shares of the biopharmaceutical company’s stock worth $198,000 after buying an additional 8,716 shares during the period. Finally, American International Group Inc. boosted its holdings in shares of Celldex Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 58,838 shares of the biopharmaceutical company’s stock worth $212,000 after buying an additional 3,880 shares during the period. Institutional investors own 55.98% of the company’s stock.

WARNING: “Celldex Therapeutics, Inc. (CLDX) Holdings Lifted by Nationwide Fund Advisors” was first reported by Watch List News and is the property of of Watch List News. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/celldex-therapeutics-inc-cldx-holdings-lifted-by-nationwide-fund-advisors/1697375.html.

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) opened at $2.73 on Friday. Celldex Therapeutics, Inc. has a 52-week low of $2.20 and a 52-week high of $5.02.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.07. The firm had revenue of $3.90 million for the quarter, compared to analyst estimates of $1.30 million. Celldex Therapeutics had a negative net margin of 1,088.58% and a negative return on equity of 46.94%. The company’s revenue for the quarter was up 77.3% on a year-over-year basis. During the same quarter last year, the firm earned ($0.29) earnings per share. research analysts predict that Celldex Therapeutics, Inc. will post -0.97 earnings per share for the current fiscal year.

A number of analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Celldex Therapeutics in a research report on Tuesday, August 1st. ValuEngine lowered shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Zacks Investment Research lowered shares of Celldex Therapeutics from a “buy” rating to a “sell” rating in a research report on Monday, July 17th. Cantor Fitzgerald reissued a “buy” rating and issued a $9.00 price target on shares of Celldex Therapeutics in a research report on Tuesday, September 26th. Finally, BidaskClub lowered shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, July 24th. Three research analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $6.31.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Institutional Ownership by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.